Diagnostic Antibody for Type A Botulism

-
Investigator: James D. Marks, MD, PhD
Sponsor: Xoma Corporation

Location(s): United States

Description

XOMA 3AB, currently in clinical trials sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, is a first-in-class treatment for botulism poisoning. Preclinical and IND-enabling studies to date have shown that the XOMA 3AB candidate is well-tolerated and effective at neutralizing and clearing botulinum toxin (Type A) from the bloodstream in animals. 


The XOMA 3AB program is based on more than a decade of breakthrough biomedical research conducted in the laboratory of James Marks, M.D., Ph.D., Professor of Anesthesia at the University of California, San Francisco (UCSF), and on XOMA's extensive antibody development expertise and platform technologies. The UCSF preclinical research program was funded by the National Institutes of Health and Department of Defense and identified lead antibody candidates which when combined led to highly potent toxin neutralization at very low doses.